Short answer
Oric Pharmaceuticals, Inc. (ORIC) filed an 8-K current report with the SEC on June 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved amended 2020 Equity Incentive Plan effective June 18, 2026.
Oric Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Stockholders approved amended 2020 Equity Incentive Plan effective June 18, 2026
- Annual share increase changed from 5% to 4% of outstanding common shares, but 2,656,500-share cap removed
- Incentive stock option authorization capped at 10,000,000 shares, subject to plan reserve
- Restrictions eliminate repricing, award exchanges, cash settlements, and transfers of outstanding awards
- Lower annual percentage reduces dilution pace, while removing the absolute cap could permit larger future grants
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 91.36% shareholder participation; 94,571,281 shares represented at the June 18, 2026 annual meeting
- Class III directors Jacob M. Chacko and Mardi C. Dier elected through the 2029 annual meeting
- KPMG LLP ratified as independent auditor for fiscal 2026, with 94,536,096 votes in favor
- Amended 2020 Equity Incentive Plan approved, with 61,228,918 votes for versus 27,264,875 against
- Executive compensation approved; annual say-on-pay voting selected through 2032, with 89,392,979 votes for one-year frequency
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oric Pharmaceuticals, Inc. 8-K filings
Get the next ORIC 8-K as it lands
Follow ORIC for push alerts, or ask the research agent what this filing means.